Genetic testing for hereditary cancer syndromes contributes to the medical management of patients who may be at increased risk of one or more cancers. BRCA1 and BRCA2 testing for hereditary breast and ovarian cancer is one such widely used test. However, clinical testing methods with high sensitivity for deleterious mutations in these genes also detect many unclassified variants, primarily missense substitutions.

DOI: 10.1136/jmg.2005.033878
Version: za2963e q8za6 q8zb2 q8zc5 q8zd8 q8ze6 q8zfd q8zg0